Michael B.Jordan Receives ALS Advocacy Award
Table of Contents
Actor Michael B.Jordan, known for his roles in Gray’s Anatomy and Euphoria, was honored with an award for his commitment to raising awareness of Amyotrophic Lateral Sclerosis (ALS). The award was presented at the Champions for Cures and Care Gala hosted by the ALS Network.
Health Considerations and Acceptance of Award
Jordan was unable to attend the gala in person due to the physical realities of his ALS diagnosis and his overall health. According to a statement released by the ALS network, he cancelled his appearance shortly before the event. The institution expressed its gratitude for Jordan’s “courage, advocacy, and ongoing commitment to the ALS community.”
Aaron Lazar Accepts on Jordan’s Behalf
Actor Aaron Lazar, who also lives with ALS, accepted the award on Jordan’s behalf. Lazar’s personal experience with the disease underscored the importance of the recognition and the ongoing need for research and support.
jordan’s Pre-Recorded Message
Despite his inability to attend, Jordan delivered a pre-recorded video message expressing his appreciation. He dedicated the award to his family, loved ones, and all those affected by ALS, including patients, caregivers, and advocates. He emphasized the collective fight against the disease and the importance of continued progress. “This award is not only for me, but for my stunning family and loved ones who are fighting,” Jordan stated in the video. “And it is for everyone who has faced ALS with courage,every caregiver who dedicates their heart and soul day in and day out,and every advocate who stands strong for progress.”
Current Status of ALS Research and Support
The National Institute of Neurological Disorders and Stroke (NINDS) continues to fund extensive research into the causes, prevention, and treatment of ALS. As of January 25, 2026, there is no cure for ALS, but ongoing clinical trials are investigating potential therapies.Organizations like the ALS Association provide support services for patients and families affected by the disease, and also funding for research. Recent advancements include the FDA approval of Relyvrio,a medication shown to modestly slow the progression of ALS in some patients.
